跳至主要内容
临床试验/NCT02399046
NCT02399046已完成不适用

A Prospective, Randomized, Multicenter, Controlled Study Comparing the Outcomes of Primary Total Knee Arthroplasty Devices Manufactured in China Versus Devices Manufactured Outside of China

Johnson & Johnson Medical (Suzhou) Ltd.9 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2017年8月17日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
160
试验地点
9
主要终点
12-month post-op AKS

研究概览

简要总结

A clinical trial of total knee system used in Primary Total Knee Arthroplasty in China.

详细描述

A prospective, Randomized, Multicenter, Controlled Study Comparing the Outcomes of Primary Total Knee Arthroplasty Devices Manufactured in China versus Devices Manufactured Outside of China.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • . The subject is ≥18years old
  • . The Subject must be of Chinese ethnic descent and be willing to return on three occasions for clinical evaluations.
  • . Subject is a suitable candidate for cemented primary TKA using the devices described in this CIP with either resurfaced or non-resurfaced patellae.
  • . Subject must meet all criteria specified in BOTH China Knee stem and P.F.C.® Sigma knee instructions for use (IFU)
  • . Before surgery, subject is willing and able to sign the informed consent form approved by the Institutional Review Board (IRB), Ethics Committee (EC) or Ethical Review Board (ERB).
  • . Subject, in the opinion of the Clinical Investigator, is able to understand this clinical investigation and co-operate with investigational procedures.
  • . Subject must be comfortable with speaking, reading, and understanding questions and providing responses in an available translated language for the patient reported outcomes (PROs) in the CIP.
  • . Subject is receiving a unilateral knee replacement or, if a contralateral knee replacement is anticipated, the surgery must occur within 6 months of the first study knee TKA. The second knee will not be enrolled in the study.

排除标准

  • Subject does not provide written voluntary consent to participate in the clinical study.
  • The Subject is a woman who is pregnant or lactating.
  • Subject is anticipated to require a contralateral TKA between 6 months and 1 year.
  • Contralateral knee has already been enrolled in this study.
  • Previous partial knee replacement (unicompartmental, bicompartmental or patellofemoral joint replacement), patellectomy, high tibial osteotomy or primary TKA in affected knee.
  • Subject has a malignant disease, severe condition, alcohol or drug addiction and/or mental disorders that the investigator believes will interfere with the study participation.
  • Subjects with severe osteoporosis, metabolic bone disease, radioactive bone disease or tumor in bone surrounding knee joint that, in the opinion of the investigator, will negatively impact implant fixation and the outcome of the investigation
  • Subject has significant neurological or musculoskeletal disorders or disease that may adversely affect gait or weight bearing (e.g. muscular dystrophy, multiple sclerosis, cerebral infarction, hemiplegia, Charcot disease).
  • Subject is not comfortable with speaking, reading, and understanding questions and providing responses in an available translated language for the PROs in the CIP.
  • Subject has a medical condition with less than 2 years of life expectancy.
  • The Subject has comorbid condition(s) that could limit the Subject's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study.
  • The Subject is currently participating in another investigational drug or device study.
  • Subject is a prisoner.
  • The Subject has a known allergy to any implant components (metal for example).
  • Hemoglobin < 11 g/dL
  • Albumin < 90% normal low limit
  • CRP > 2 times normal upper limit
  • ESR > 2 times normal upper limit
  • Subjects who have abnormal coagulation exam results and cannot be corrected by drugs or plasma replacement

结局指标

主要结局

12-month post-op AKS

时间窗: 12 months postoperatively

次要结局

  • One year non-revision rate where revision is defined as removal of any component secondary to infection(12 months postoperatively)
  • Short-form 12(SF-12) general health questionnaire each of 8 dimensions and the overall Physical and Mental health domains, at 1-year follow-up interval.(Preoperation to12 months postoperatively)
  • WOMAC scores at the 1-year follow-up interval(Preoperation to12 months postoperatively)
  • Non-revision rates(revision for any reason) through the end of the study(12 months postoperatively)
  • Radiogrphic assessment of clinically relevant radiolucent line(RLL)and osteolysis,migration and subsidence, by comparing the 3 month post-operative x-ray to the 1 year follow up x-ray inerval.(Preoperation to12 months postoperatively)
  • American Knee Society Total Score success (where success is defined as a score of 80 points or higher)at the 1 year follow-up inerval(12 months postoperatively)

研究者

发起方
Johnson & Johnson Medical (Suzhou) Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (9)

Loading locations...

相似试验